149 related articles for article (PubMed ID: 8784140)
1. Effect of BQ-123 and tissue plasminogen activator on vasospasm after subarachnoid hemorrhage in monkeys.
Kim CJ; Bassiouny M; Macdonald RL; Weir B; Johns LM
Stroke; 1996 Sep; 27(9):1629-33. PubMed ID: 8784140
[TBL] [Abstract][Full Text] [Related]
2. Prospective, randomized, double-blind trial of BQ-123 and bosentan for prevention of vasospasm following subarachnoid hemorrhage in monkeys.
Hino A; Weir BK; Macdonald RL; Thisted RA; Kim CJ; Johns LM
J Neurosurg; 1995 Sep; 83(3):503-9. PubMed ID: 7666230
[TBL] [Abstract][Full Text] [Related]
3. Effect of intrathecal thrombolytic therapy on subarachnoid clot and chronic vasospasm in a primate model of SAH.
Findlay JM; Weir BK; Steinke D; Tanabe T; Gordon P; Grace M
J Neurosurg; 1988 Nov; 69(5):723-35. PubMed ID: 3141595
[TBL] [Abstract][Full Text] [Related]
4. Effects of unilateral intrathecal administrations of low dose tissue-type plasminogen activator on clot lysis, vasospasm and brain phospholipid hydroperoxidation in a primate model of bilateral subarachnoid hemorrhage.
Suzuki H; Kanamaru K; Kuroki M; Sun H; Waga S; Miyazawa T
Neurol Res; 1998 Oct; 20(7):625-31. PubMed ID: 9785591
[TBL] [Abstract][Full Text] [Related]
5. The effect of timing of intrathecal fibrinolytic therapy on cerebral vasospasm in a primate model of subarachnoid hemorrhage.
Findlay JM; Weir BK; Kanamaru K; Grace M; Baughman R
Neurosurgery; 1990 Feb; 26(2):201-6. PubMed ID: 2106630
[TBL] [Abstract][Full Text] [Related]
6. Comparison of intrathecal administration of urokinase and tissue plasminogen activator on subarachnoid clot and chronic vasospasm in a primate model.
Hariton GB; Findlay JM; Weir BK; Kasuya H; Grace MG; Mielke BW
Neurosurgery; 1993 Oct; 33(4):691-6; discussion 696-7. PubMed ID: 8232810
[TBL] [Abstract][Full Text] [Related]
7. Effect of endothelinA-receptor antagonist BQ-123 and phosphoramidon on cerebral vasospasm.
Cosentino F; McMahon EG; Carter JS; Katusić ZS
J Cardiovasc Pharmacol; 1993; 22 Suppl 8():S332-5. PubMed ID: 7509979
[TBL] [Abstract][Full Text] [Related]
8. Reversal of cerebral vasospasm using an intrathecally administered nitric oxide donor.
Wolf EW; Banerjee A; Soble-Smith J; Dohan FC; White RP; Robertson JT
J Neurosurg; 1998 Aug; 89(2):279-88. PubMed ID: 9688124
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of intrathecal thrombolytic therapy in a primate model of cerebral vasospasm.
Findlay JM; Weir BK; Gordon P; Grace M; Baughman R
Neurosurgery; 1989 Apr; 24(4):491-8. PubMed ID: 2496328
[TBL] [Abstract][Full Text] [Related]
10. Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolytic therapy with tissue-type plasminogen activator.
Mizoi K; Yoshimoto T; Takahashi A; Fujiwara S; Koshu K; Sugawara T
J Neurosurg; 1993 Mar; 78(3):430-7. PubMed ID: 8433145
[TBL] [Abstract][Full Text] [Related]
11. Thrombolytic therapy with tissue plasminogen activator for prevention of vasospasm in experimental subarachnoid hemorrhage: its efficacy and problems.
Asada M; Kong J; Nakamura M; Tamaki N
Neurol Res; 1996 Aug; 18(4):342-4. PubMed ID: 8875453
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage.
Seifert V; Eisert WG; Stolke D; Goetz C
Neurosurgery; 1989 Oct; 25(4):590-8. PubMed ID: 2507953
[TBL] [Abstract][Full Text] [Related]
13. Cerebral perivascular nerves in subarachnoid hemorrhage. A histochemical and immunohistochemical study.
Hara H; Nosko M; Weir B
J Neurosurg; 1986 Oct; 65(4):531-9. PubMed ID: 3760964
[TBL] [Abstract][Full Text] [Related]
14. Failure of intracisternal tissue plasminogen activator to prevent vasospasm in certain patients with aneurysmal subarachnoid hemorrhage.
Steinberg GK; Vanefsky MA; Marks MP; Adler JR; Koenig GH
Neurosurgery; 1994 May; 34(5):809-13; discussion 813-4. PubMed ID: 8052377
[TBL] [Abstract][Full Text] [Related]
15. Antisense preproendothelin-oligoDNA therapy for vasospasm in a canine model of subarachnoid hemorrhage.
Ohkuma H; Parney I; Megyesi J; Ghahary A; Findlay JM
J Neurosurg; 1999 Jun; 90(6):1105-14. PubMed ID: 10350259
[TBL] [Abstract][Full Text] [Related]
16. Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose study and review of endothelin-based therapies in the literature on cerebral vasospasm.
Wanebo JE; Arthur AS; Louis HG; West K; Kassell NF; Lee KS; Helm GA
Neurosurgery; 1998 Dec; 43(6):1409-17; discussion 1417-8. PubMed ID: 9848855
[TBL] [Abstract][Full Text] [Related]
17. Effect of intrathecal superoxide dismutase and catalase on oxyhemoglobin-induced vasospasm in monkeys.
Macdonald RL; Weir BK; Runzer TD; Grace MG; Poznansky MJ
Neurosurgery; 1992 Apr; 30(4):529-39. PubMed ID: 1584351
[TBL] [Abstract][Full Text] [Related]
18. Intrathecal fibrinolytic therapy after subarachnoid hemorrhage: dosage study in a primate model and review of the literature.
Findlay JM; Weir BK; Kanamaru K; Grace M; Gordon P; Baughman R; Howarth A
Can J Neurol Sci; 1989 Feb; 16(1):28-40. PubMed ID: 2493974
[TBL] [Abstract][Full Text] [Related]
19. The role of endothelin and nitric oxide in modulation of normal and spastic cerebral vascular tone in the dog.
Hirose H; Ide K; Sasaki T; Takahashi R; Kobayashi M; Ikemoto F; Yano M; Nishikibe M
Eur J Pharmacol; 1995 Apr; 277(1):77-87. PubMed ID: 7635177
[TBL] [Abstract][Full Text] [Related]
20. Innovations in aneurysmal subarachnoid hemorrhage: intracisternal t-PA for the prevention of vasospasm.
Bell TE; Kongable GL
J Neurosci Nurs; 1996 Apr; 28(2):107-13. PubMed ID: 8718759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
